Sera Prognostics (SERA) to Release Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative return on equity of 45.74% and a negative net margin of 11,843.79%. On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sera Prognostics Stock Performance

NASDAQ:SERA opened at $9.92 on Tuesday. The firm has a 50-day simple moving average of $9.62 and a two-hundred day simple moving average of $6.56. Sera Prognostics has a fifty-two week low of $1.52 and a fifty-two week high of $12.35.

Insider Buying and Selling

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 38,899 shares of Sera Prognostics stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total value of $364,483.63. Following the completion of the sale, the chief executive officer now owns 908,104 shares of the company’s stock, valued at approximately $8,508,934.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider John J. Boniface sold 21,438 shares of the business’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $9.55, for a total transaction of $204,732.90. Following the completion of the transaction, the insider now directly owns 143,524 shares of the company’s stock, valued at $1,370,654.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Zhenya Lindgardt sold 38,899 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total transaction of $364,483.63. Following the completion of the sale, the chief executive officer now owns 908,104 shares in the company, valued at approximately $8,508,934.48. The disclosure for this sale can be found here. Insiders sold a total of 92,903 shares of company stock worth $866,284 in the last three months. Insiders own 15.80% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.